Remdesivir approved for use in hospitalized COVID-19 patients

The US Food and Drug Administration on Thursday approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease, Reuters reports.

Gilead said it is currently meeting real-time demand for remdesivir, which is sold under the brand name Veklury, in the United States and anticipates meeting global demand by the end of October.